<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468465</url>
  </required_header>
  <id_info>
    <org_study_id>FFIS/2017/01/SLT</org_study_id>
    <secondary_id>2017-000605-20</secondary_id>
    <nct_id>NCT03468465</nct_id>
  </id_info>
  <brief_title>Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome</brief_title>
  <acronym>SOLITENS</acronym>
  <official_title>Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve (T-PTNS) for Solifenacin 10 mg. in the Treatment of Hyperactive Bladder Syndrome: no Inferiority Phase IV Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To determine if the T-PTNS is not inferior in the short term (3 months) to one of the
           usual pharmacological treatments (Solifenacin) in the treatment of hyperactive bladder
           syndrome and with respect to the percentage of patients that improve 50% any of the 3
           signs (Urinary frequency, diurnal / nocturnal frequency, urgency and urinary
           incontinence).

        -  To determine prognostic factors associated with insufficient improvement (less than 50%
           in the 3 main signs of hyperactive bladder syndrome (urinary frequency, urgency and
           urinary incontinence frequency) after treatment with T-PTNS and Solifenacin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to receive the usual standard treatment with Solifenacin or
      treatment based on peripheral unilateral transcutaneous neuromodulation of the posterior
      tibial nerve .
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate whether treatment with T-PTNS is not less than 3 months compared to the current standard pharmacological treatments regarding the episodes of urgency, urinary frequency, incontinence and nocturia, all measured with the 3-day voiding diary</measure>
    <time_frame>12 weeks</time_frame>
    <description>3- day voiding diary</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Medical device: Transcutaneous electrical neurostimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medical device 4 weeks with daily sessions of 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg tablet daily during 75 days maximum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin Succinate</intervention_name>
    <description>10 mg tablet daily during 75 days maximum</description>
    <arm_group_label>Solifenacin</arm_group_label>
    <other_name>Vesicare</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neuro-Muscular Stimulators (NMS)</intervention_name>
    <description>Treatment with T-PTNS will include a first induction period of 4 weeks with daily sessions of 30 minutes duration and performed at each subject's home (Monday through Friday, resting weekends) and a second recall period of 2 additional months, with a session every 4 weeks that will be held at the healthcare center. In total there will be 20 sessions in the induction period and 2 in the recall period</description>
    <arm_group_label>Medical device: Transcutaneous electrical neurostimulation</arm_group_label>
    <other_name>T-PTNS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women&gt; 18 years, diagnosed with hyperactive bladder syndrome for at least 6 months of
             evolution and who have taken Beta 3 agonists

        Exclusion Criteria:

          -  Patients who can contribute biased information: have previously consumed and abandoned
             anticholinergic drugs due to lack of efficacy or side effects; Suffering from
             hyperactive bladder of neurogenic origin (multiple sclerosis, Parkinson's, spinal cord
             injury); Present cystocele or any pelvic organ prolapse&gt; 2 according to Pelvic Organ
             Prolapse-Q classification

          -  Patients who may become worse with the interventions envisaged in the study: being a
             implantable automatic defibrillators; With cutaneous alterations in lower extremities
             that prevent the placement of electrodes on the surface; Women who are pregnant or who
             may be pregnant during the duration of the clinical trial (prior and at each
             evaluation visit urine Bhcg will be requested to rule out pregnancy) or patients who
             are not able to manage transcutaneous electrical neurostimulation on an outpatient
             basis ) Or patients in whom Solifenacin is contraindicated: urinary retention, severe
             gastrointestinal disorders (including toxic megacolon), myasthenia gravis, or
             narrow-angle glaucoma, and in patients at risk of these conditions as hypersensitive
             at first Active or to any of the excipients, undergoing hemodialysis, with moderate
             hepatic insufficiency or severe renal insufficiency or in simultaneous treatment with
             a potent inhibitor of CYP3A4, eg ketoconazole.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José David Jiménez Parra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Rafael Méndez (Lorca, Murcia. SPAIN)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María Luisa María Luisa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínica Universitario Virgen de la Arrixaca (SPAIN)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Felix Escudero Bregante, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario Virgen de la Arrixaca (SPAIN)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julián Oñate, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Reina Sofía (SPAIN)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Isabel López López, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario San Juan (SPAIN)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mª Luisa Sánchez Ferrer, MD</last_name>
    <phone>+34 968 369065</phone>
    <email>marisasanchezferrer1@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínico Universtario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mª Luisa Sánchez Ferrer, MD</last_name>
      <phone>34 968 369065</phone>
      <email>marisasanchezferrer1@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>José David Jiménez Parra, MD</last_name>
      <email>jdjimenez@hotmail.es</email>
    </contact_backup>
    <investigator>
      <last_name>Mª Luisa Sánchez Ferrer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Felix Escudero Bregante, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José David Jiménez Parra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julián Oñate, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Isabel López López, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperactive Bladder Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

